20. Use of any one of claims 1 to 19 wherein a first quantity of 5-fluorouracil (5-FU) is to be administered intravenously immediately after aflibercept administration and a second quantity of 5-FU is to be administered intravenously after the first quantity in continuous infusion.

21. Use of any one of claims 1 to 20 wherein about 400 mg/m^2 of 5-fluorouracil (5-FU) is to be administered intravenously over a period of 2 to 4 minutes after aflibercept administration and wherein 2400 mg/m^2 of 5-FU is to be administered intravenously over almost 46 hours after the administration of the 400 mg/m^2 in continuous infusion.

22. Use of any one of claims 1 to 21 wherein the patient has liver metastases.

23. Use of a composition comprising aflibercept in combination with folinic acid, 5-fluorouracil (5-FU) and irinotecan in the manufacture of a medicament for treating CRC, wherein the composition is for simultaneous administration.

24. Use of a composition comprising aflibercept in combination with folinic acid, 5-fluorouracil (5-FU) and irinotecan in the manufacture of a medicament for treating CRC, wherein the composition is for sequential administration.

25. Use of a composition comprising aflibercept in combination with folinic acid, 5-fluorouracil (5-FU) and irinotecan in the manufacture of a medicament for treating CRC, wherein the composition is for administration spaced out over a period of time so as to obtain the maximum efficacy of the combination.

26. An article of manufacture for use in treating Colorectal Cancer (CRC) comprising:

a) a packaging material

b) aflibercept, folinic acid, 5-fluorouracil (5-FU) and irinotecan; and

c) a label or package insert contained within said packaging material indicates that aflibercept in combination with folinic acid, 5-fluorouracil (5-FU) and irinotecan is effective for the treatment of CRC in the manufacture of an article for treating CRC.

27. An article of manufacture for use according to claim 26, wherein said treatment of CRC comprises improvement in Overall Survival (OS).

28. An article of manufacture for use according to claim 26, wherein said treatment of CRC comprises improvement in Progression Free Survival (PFS).

29. An article of manufacture for use according to claim 26, wherein said treatment of CRC comprises improvement in Overall Response Rate (ORR).

30. Composition comprising therapeutically effective amounts of aflibercept in combination with folinic acid, 5-fluorouracil (5-FU) and irinotecan and comprising a pharmaceutically acceptable carrier for treating patients with CRC.

31. A kit for use in treating patients with CRC comprising:

a) ~~at least one~~ the compounds ~~chosen from the list consisting of~~ aflibercept, folinic acid, 5-fluorouracil (5-FU) and irinotecan; and

b) a label or package insert contained within said kit indicating that aflibercept is to be used in combination with folinic acid, 5-fluorouracil (5-FU) and irinotecan (FOLFIRI) or that folinic acid, 5-fluorouracil (5-FU) and irinotecan (FOLFIRI) is to be used in combination with Aflibercept.

32. A kit comprising in separate containers pharmaceutical compositions for combined use in treating CRC in a patient which comprises (1) a pharmaceutical composition comprising aflibercept , (2) a pharmaceutical composition comprising folinic acid, (3) a pharmaceutical composition comprising 5-fluorouracil (5-FU) and (4) a pharmaceutical composition comprising irinotecan.